FDA Grants Brukinsa Priority Review After Chemo-Free Regimen Beats Standard Care in Mantle Cell Lymphoma
· techtimes.com · popularity 21/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at techtimes.com →
Summary
FDA granted Brukinsa Priority Review for mantle cell lymphoma after Phase 3 trial showed a chemo-free regimen reduced disease progression risk by 43%.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 1.